Abstract

Objectives

This retrospective claims-based analysis explored the association of treatment-free interval (TFI) with healthcare resource utilization (HCRU) and direct medical costs among patients with advanced endometrial cancer (EC) who reached at least a second line of therapy.

Methods

Data were derived from the 100% Medicare Fee-for-Service database and MORE Registry of closed claims. Eligible patients had an EC diagnosis between January 1, 2016, and June 30, 2021, with continuous enrollment benefits for ≥12 months preceding and ≥30 days following second-line therapy initiation. All-cause and EC-specific HCRU per patient per month were summarized descriptively for TFI cohorts of 6 or ≥6 months. Generalized linear models assessed the association between TFI and costs, adjusting for patient characteristics.

Results

Of 2484 patients included, 2102 (85%) had a TFI of .0001).

Conclusions

Patients with advanced EC initiating subsequent treatment face considerable HCRU and costs. Because most patients had a 6-month TFI, which is indicative of faster disease progression and associated with numerically higher HCRU and significantly higher EC-specific costs, this study suggests that effective up-front treatments may help alleviate this burden.